Antisoma plc - Product Pipeline Review - Q1 2011

Global Markets Direct, May 2011, Pages: 58

Antisoma plc – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Antisoma plc - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Antisoma plc - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Antisoma plc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Antisoma plc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Antisoma plc’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Antisoma plc’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Antisoma plc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Antisoma plc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Antisoma plc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Antisoma plc and identify potential opportunities in those areas.

Table of Content
Table of Content
List of Tables
List of Figures
Antisoma plc Snapshot
Antisoma plc Overview
Key Information
Key Facts
Antisoma plc – Research and Development Overview
Key Therapeutic Areas
Antisoma plc – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Antisoma plc – Pipeline Products Glance
Antisoma plc Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Antisoma plc–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Antisoma plc – Drug Profiles
AS1411
Product Description
Mechanism of Action
R&D Progress
DMXAA + Carboplatin + Paclitaxel
Product Description
Mechanism of Action
R&D Progress
Symadex
Product Description
Mechanism of Action
R&D Progress
Dendritic Cell Auto-Immune Modulators
Product Description
Mechanism of Action
R&D Progress
PPM1D Inhibitor Programme
Product Description
Mechanism of Action
R&D Progress
Antisoma plc – Pipeline Analysis
Antisoma plc – Pipeline Products by Therapeutic Class
Antisoma plc - Pipeline Products By Target
Antisoma plc – Pipeline Products by Route of Administration
Antisoma plc – Pipeline Products by Molecule Type
Antisoma plc – Recent Pipeline Updates
Antisoma plc - Dormant Projects
Antisoma plc - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
AS1406
AS1402 + Letrozole
AS1405
AS1410
AS1411
AS1411 + Cytarabine
AS1413
AS1413 + Cytarabine
R1549
Symadex
Antisoma plc – Company Statement
Antisoma plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Antisoma plc, Deals Summary, 2004 to 2011
Antisoma plc Detailed Deal Summary
Asset Purchase
Antisoma Sells Oral Fludarabine To sanofi-aventis U.S.
Antisoma Sells Oforta Rights To Sanofi-Aventis
Antisoma Acquires Royalty Rights To R1549 And R1550 From Inverness
Acquisition
Antisoma Completes Acquisition Of Xanthus Pharmaceuticals
Antisoma Acquires Aptamera
Equity Offering
Antisoma Completes Private Placement Of $41 Million
Antisoma Completes Private Placement Of $51.7 Million
Antisoma Completes Public Offering Of Its Common Stock For $51.69 Million
Antisoma Completes Private Placement Of $11 Million
Licensing Agreements
Antisoma Enters Into Licensing Agreement With Bryan Oncor
Antisoma Enters Into Licensing Agreement With The Institute of Cancer Research And Cancer Research Technology
Antisoma Enters Into Licensing Agreement With Betagenon
Novartis Enters Into Licensing Agreement With Antisoma
Antisoma Enters Into Licensing Agreement With EMD Lexigen Research Center
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Antisoma plc – Pipeline by Therapy Area and Indication, 2011
Antisoma plc – Pipeline by Stage of Development, 2011
Antisoma plc – Monotherapy Products in Pipeline, 2011
Antisoma plc – Combination Treatment Modalities in Pipeline, 2011
Antisoma plc - Phase II, 2011
Antisoma plc - Phase I, 2011
Antisoma plc - Pipeline By Therapeutic Class, 2011
Antisoma plc - Pipeline By Target, 2011
Antisoma plc – Pipeline By Route of Administration, 2011
Antisoma plc – Pipeline By Molecule Type, 2011
Antisoma plc – Recent Pipeline Updates, 2011
Antisoma plc - Dormant Developmental Projects, 2010
Antisoma plc - Discontinued Pipeline Products, 2010
Antisoma plc, Other Locations
Antisoma plc, Subsidiaries
Antisoma plc, Deals Summary, 2004 to 2011

List of Figures
Antisoma plc – Pipeline by Therapy Area and Indication, 2011
Antisoma plc – Pipeline by Stage of Development, 2011
Antisoma plc – Monotherapy Products in Pipeline, 2011
Antisoma plc – Combination Treatment Modalities in Pipeline, 2011
Antisoma plc – Pipeline By Therapeutic Class, 2011
Antisoma plc - Pipeline By Target, 2011
Antisoma plc – Pipeline By Route of Administration, 2011
Antisoma plc – Pipeline By Molecule Type, 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Ixia - Company Analysis
• SunGard - Profile - US
• Scientific Games Corporation - Company Analysis
• eBay - Strong Execution
• Insight into Samsung Electronics' Notebook PC Business Model
• Amazon - Point of Realization in 2013?
• Accenture plc,(ACN) Profile and Financials, plus E-Commerce & Internet Industry Trends Analysis, Operating Ratio and Financial Averages